Trial · NCT02935894
Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat
NCT02935894, Not applicable, Completed, USDA, Western Human Nutrition Research Center; results first posted 2018-06-01
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat. Trials, record NCT02935894. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02935894
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat
- NCT number
- NCT02935894
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 14 participants, actual
- Lead sponsor
- USDA, Western Human Nutrition Research Center
- Conditions
- Stability & Variability of Lipid-derived Molecules in Sweat
- Interventions
- Ibuprofen, Physiological induction of sweating, Pilocarpine
- First posted
- 2016-10-18
- Last updated
- 2018-06-01
- Results first posted
- 2018-06-01
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 1, 2 and 3; detected lipid mediator concentrations for study visit 1 reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
| Primary | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | measured at study visit 1, detected lipid mediator concentrations reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
| Primary | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 1, detected lipid mediator concentrations reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
| Primary | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 2, detected lipid mediator concentrations reported | Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids. |
| Primary | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported | Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules. |
| Secondary | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported | Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules. |
| Secondary | Change in Plasma Ibuprofen Concentrations | measured at four timepoints at study visit 4 | Plasma concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration |
| Secondary | Change in Sweat Ibuprofen Concentrations | measured at four timepoints at study visit 4 | Sweat concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 1, 2 and 3; detected lipid mediator concentrations for study visit 1 reported | Of the 14 subjects recruited for this study, only 7 provided usable data for this primary outcome. | picomoles per milliliter | MEAN |
| PRIMARY | Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise | measured at study visit 1, detected lipid mediator concentrations reported | Of the 14 subjects recruited for this study, only 7 provided usable data for this primary outcome. | picomoles per milliliter | MEAN |
| PRIMARY | Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 1, detected lipid mediator concentrations reported | Of the 14 subjects recruited for this study, only 4 provided usable data for this primary outcome. | picomoles per milliliter | MEAN |
| PRIMARY | Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | measured at study visit 2, detected lipid mediator concentrations reported | Of the 14 subjects recruited for this study, only 4 provided usable data for this primary outcome. | picomoles per milliliter | MEAN |
| PRIMARY | Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported | Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome. | picomoles per milliliter | GEOMETRIC_MEAN |
| SECONDARY | Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration | measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reported | Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome. | picomoles per milliliter | GEOMETRIC_MEAN |
| SECONDARY | Change in Plasma Ibuprofen Concentrations | measured at four timepoints at study visit 4 | Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome. | micrograms per milliliter | GEOMETRIC_MEAN |
| SECONDARY | Change in Sweat Ibuprofen Concentrations | measured at four timepoints at study visit 4 | Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome. | micrograms per milliliter | GEOMETRIC_MEAN |
Source ClinicalTrials.gov
Results by group338
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 9-HODE | 20 | Standard Deviation 9.8 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 13-HODE | 46 | Standard Deviation 28 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 9-HOTrE | 2.2 | Standard Deviation 1.2 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 13-HOTrE | 3.5 | Standard Deviation 1.8 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 5-HETE | 0.1 | Standard Deviation 0.07 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 8-HETE | 0.23 | Standard Deviation 0.062 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 9-HETE | 0.12 | Standard Deviation 0.062 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 11-HETE | 0.15 | Standard Deviation 0.055 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 12-HETE | 0.85 | Standard Deviation 0.94 | picomoles per milliliter |
| Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation | Single Group | 15-HETE | 0.43 | Standard Deviation 0.25 | picomoles per milliliter |
1 to 10 of 338Source ClinicalTrials.gov
See all 338 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Single Group | 14 | |
| Overall Study | COMPLETED | Single Group | 13 | |
| Overall Study | NOT COMPLETED | Single Group | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Single Group | 0 | 14 |
| Total, other adverse events | Single Group | 0 | 14 |
| Total, serious adverse events | Single Group | 0 | 14 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02935894
GET https://conductscience.org/api/trials/v1/NCT02935894/results?page=2